Intercept Pharma (ICPT) Estimates Raised At Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intercept Pharmaceuticals (ICPT) PT Raised to $149 at Cowen
February 19, 2019 4:12 PM ESTCowen analyst Ritu Baral raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $149.00 (from $120.00) while maintaining a Outperform rating.
The analyst commented, "ICPT's Ph3 NASH trial REGENERATE reported positive data this morning, achieving statistically significant fibrosis (with no... More
Intercept Pharmaceuticals (ICPT) PT Raised to $248 at Wedbush
February 19, 2019 1:57 PM ESTWedbush analyst Liana Moussatos raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $248.00 (from $220.00) while maintaining a Outperform rating.
... MoreIntercept Pharmaceuticals (ICPT) PT Raised to $175 at Oppenheimer; 'REGENERATE Top Line Sparks Joy'
February 19, 2019 1:03 PM ESTOppenheimer analyst Jay Olson raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $175.00 (from $140.00) while maintaining a Outperform rating.
The analyst commented, "Top line results from the Ph3 REGENERATE study of OCA in NASH were stat sig for Fibrosis... More
Intercept Pharmaceuticals (ICPT) Bullish View Reiterated at Needham & Company on Positive Positive Phase 3 REGENERATE NASH Trial
February 19, 2019 10:42 AM ESTNeedham & Company analyst Alan Carr reiterated a Buy rating and $150 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after the company announced this morning that one of the two primary endpts of the Phase 3 REGENERATE trial in F2/F3 NASH was met w/ the highest dose tested (25mg QD Obeticholic... More
